Home › Funds › LOOMIS SAYLES & CO L P › VRTX

LOOMIS SAYLES & CO L P position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

LOOMIS SAYLES & CO L P reported holding 3,618,820 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$1.89B, representing 2.46% of its reported portfolio and ranking #13 among its reported holdings. LOOMIS SAYLES & CO L P has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.62M sh
Reported value held$1.89B
Portfolio Weight2.46%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How LOOMIS SAYLES & CO L P's VRTX position evolved

LOOMIS SAYLES & CO L P first disclosed a stake in VRTX in Q3 2023 at 3,163,468 shares (US$1.10B). The position peaked in Q2 2026 at 3,920,953 shares, worth US$1.95B. Across 13 filings, LOOMIS SAYLES & CO L P increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,618,820 shares valued at US$1.89B — a reduction of -302,133 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.16M $1.10B New
Q4 2023 3.13M $1.28B Reduce
Q1 2024 3.11M $1.30B Reduce
Q2 2024 3.14M $1.47B Add
Q3 2024 3.07M $1.43B Reduce
Q4 2024 3.77M $1.52B Add
Q1 2025 3.75M $1.82B Reduce
Q2 2025 3.81M $1.70B Add
Q3 2025 4.12M $1.61B Add
Q4 2025 4.03M $1.83B Reduce
Q1 2026 4.00M $1.79B Reduce
Q2 2026 3.92M $1.95B Reduce
Q3 2026 3.62M $1.89B Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has LOOMIS SAYLES & CO L P held VRTX?

LOOMIS SAYLES & CO L P has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is LOOMIS SAYLES & CO L P's current position in VRTX?

As of Q3 2026, LOOMIS SAYLES & CO L P holds 3.62M shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $1.89B, representing 2.46% of its reported portfolio and ranking #13.

Has LOOMIS SAYLES & CO L P been buying or selling VRTX?

In the latest 13F filing (Q3 2026), LOOMIS SAYLES & CO L P reduced its position in VRTX. The position peaked in Q2 2026 at 3.92M shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.